8. Literaturverzeichnis

Abdel-Hafiz,HA, C Y Chen, T Marcell, D J Kroll, J P Hoeffler, 1993, Structural determinants outside of the leucine zipper influence the interactions of CREB and ATF-2: interaction of CREB with ATF-2 blocks E1a-ATF-2 complex formation: Oncogene, v. 8, p. 1161-1174.

Adachi,Y, P N Reynolds, M Yamamoto, M Wang, K Takayama, S Matsubara, T Muramatsu, D T Curiel, 2001, A Midkine Promoter-based Conditionally Replicative Adenovirus for Treatment of Pediatric Solid Tumors and Bone Marrow Tumor Purging: Cancer Res., v. 61, p. 7882-7888.

Addison,CL, J L Bramson, M M Hitt, W J Muller, J Gauldie, F L Graham, 1998, Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors: Gene Ther., v. 5, p. 1400-1409.

Agha-Mohammadi,S, M T Lotze, 2000, Regulatable systems: applications in gene therapy and replicating viruses: J.Clin.Invest, v. 105, p. 1177-1183.

Alemany,R, C Balague, D T Curiel, 2000, Replicative adenoviruses for cancer therapy: Nat.Biotechnol., v. 18, p. 723-727.

Alemany,R, S Lai, Y C Lou, H Y Jan, X Fang, W W Zhang, 1999, Complementary adenoviral vectors for oncolysis: Cancer Gene Ther., v. 6, p. 21-25.

Allay,JA, M S Steiner, Y Zhang, C P Reed, J Cockroft, Y Lu, 2000, Adenovirus p16 gene therapy for prostate cancer: World J.Urol., v. 18, p. 111-120.

Angeletti,PC, J A Engler, 1998, Adenovirus preterminal protein binds to the CAD enzyme at active sites of viral DNA replication on the nuclear matrix: J.Virol., v. 72, p. 2896-2904.

Baron,U, H Bujard, 2000, Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances: Methods Enzymol., v. 327, p. 401-421.

Baron,U, D Schnappinger, V Helbl, M Gossen, W Hillen, H Bujard, 1999, Generation of conditional mutants in higher eukaryotes by switching between the expression of two genes: Proc.Natl.Acad.Sci.U.S.A, v. 96, p. 1013-1018.

Berk,AJ, T G Boyer, A N Kapanidis, R H Ebright, N N Kobayashi, P J Horn, S M Sullivan, R Koop, M A Surby, S J Triezenberg, 1998, Mechanisms of viral activators: Cold Spring Harb.Symp.Quant.Biol., v. 63, p. 243-252.

Bett,AJ, L Prevec, F L Graham, 1993, Packaging capacity and stability of human adenovirus type 5 vectors: J.Virol., v. 67, p. 5911-5921.

Bischoff,JR, D H Kirn, A Williams, C Heise, S Horn, M Muna, L Ng, J A Nye, A Sampson-Johannes, A Fattaey, F McCormick, 1996, An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]: Science, v. 274, p. 373-376.

Blagosklonny,MV, P Giannakakou, M Wojtowicz, L Y Romanova, K B Ain, S E Bates, T Fojo, 1998, Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells: J.Clin.Endocrinol.Metab, v. 83, p. 2516-2522.

Bohl,D, A Salvetti, P Moullier, J M Heard, 1998, Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector: Blood, v. 92, p. 1512-1517.

Boyer,JL, G Ketner, 2000, Genetic analysis of a potential zinc-binding domain of the adenovirus E4 34k protein: J.Biol.Chem., v. 275, p. 14969-14978.

Burcin,MM, G Schiedner, S Kochanek, S Y Tsai, B W O'Malley, 1999, Adenovirus-mediated regulable target gene expression in vivo: Proc.Natl.Acad.Sci.U.S.A, v. 96, p. 355-360.

Casado,E, J Gomez-Navarro, M Yamamoto, Y Adachi, C J Coolidge, W O Arafat, S D Barker, M H Wang, P J Mahasreshti, A Hemminki, M Gonzalez-Baron, M N Barnes, T B Pustilnik, G P Siegal, R D Alvarez, D T Curiel, 2001, Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications: Clin.Cancer Res., v. 7, p. 2496-2504.

Catalona,WJ, 1994, Management of cancer of the prostate: N.Engl.J.Med., v. 331, p. 996-1004.

Chen,Y, T DeWeese, J Dilley, Y Zhang, Y Li, N Ramesh, J Lee, R Pennathur-Das, J Radzyminski, J Wypych, D Brignetti, S Scott, J Stephens, D B Karpf, D R Henderson, D C Yu, 2001, CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity: Cancer Res., v. 61, p. 5453-5460.

Cirielli,C, K Inyaku, M C Capogrossi, X Yuan, J A Williams, 1999, Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma: J.Neurooncol., v. 43, p. 99-108.

Claudio,PP, L Fratta, F Farina, C M Howard, G Stassi, S Numata, C Pacilio, A Davis, M Lavitrano, M Volpe, J M Wilson, B Trimarco, A Giordano, G Condorelli, 1999, Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty: Circ.Res., v. 85, p. 1032-1039.

Cotten,M, J M Weber, 1995, The adenovirus protease is required for virus entry into host cells: Virology, v. 213, p. 494-502.

Crystal,RG, 1999, In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors: Cancer Chemother.Pharmacol., v. 43 Suppl, p. S90-S99.

Curiel,DT, 2000, The development of conditionally replicative adenoviruses for cancer therapy: Clin.Cancer Res., v. 6, p. 3395-3399.

Curtis,S, G W Wilkinson, D Westmoreland, 1998, An outbreak of epidemic keratoconjunctivitis caused by adenovirus type 37: J.Med.Microbiol., v. 47, p. 91-94.

de Moissac,D, H Zheng, L A Kirshenbaum, 1999, Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis: J.Biol.Chem., v. 274, p. 29505-29509.

Delatte,SJ, D J Hazen-Martin, G G Re, J R Kelly, A Sutphin, E P Tagge, 2001, Restoration of p53 function in anaplastic Wilms' tumor: J.Pediatr.Surg., v. 36, p. 43-50.

Dematteo,RP, S J McClane, K Fisher, H Yeh, G Chu, C Burke, S E Raper, 1997, Engineering tissue-specific expression of a recombinant adenovirus: selective transgene transcription in the pancreas using the amylase promoter: J.Surg.Res., v. 72, p. 155-161.

Dion,LD, K T Goldsmith, T V Strong, G Bilbao, D T Curiel, R I J Garver, 1996, E1A RNA transcripts amplify adenovirus-mediated tumor reduction: Gene Ther., v. 3, p. 1021-1025.

Doronin,K, K Toth, M Kuppuswamy, P Ward, A E Tollefson, W S Wold, 2000, Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein [In Process Citation]: J.Virol., v. 74, p. 6147-6155.

Duerksen-Hughes,PJ, T W Hermiston, W S Wold, L R Gooding, 1991, The amino-terminal portion of CD1 of the adenovirus E1A proteins is required to induce susceptibility to tumor necrosis factor cytolysis in adenovirus-infected mouse cells: J.Virol., v. 65, p. 1236-1244.

Duque,PM, C Alonso, R Sanchez-Prieto, M Quintanilla, S Ramon, S Cajal, 1998, Antitumoral effect of E1B defective adenoviruses in human malignant cells: Gene Ther., v. 5, p. 286-287.

Dyson,N, P Guida, C McCall, E Harlow, 1992, Adenovirus E1A makes two distinct contacts with the retinoblastoma protein: J.Virol., v. 66, p. 4606-4611.

Eastham,JA, W Grafton, C M Martin, B J Williams, 2000, Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer: J.Urol., v. 164, p. 814-819.

Eckner,R, M E Ewen, D Newsome, M Gerdes, J A DeCaprio, J B Lawrence, D M Livingston, 1994, Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor: Genes Dev., v. 8, p. 869-884.

Edholm,D, M Molin, E Bajak, G Akusjarvi, 2001, Adenovirus vector designed for expression of toxic proteins: J.Virol., v. 75, p. 9579-9584.

Efrat,S, D Fusco-DeMane, H Lemberg, O al Emran, X Wang, 1995, Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene: Proc.Natl.Acad.Sci.U.S.A., v. 92, p. 3576-3580.

Eiz,B, P Pring-Akerblom, 1997, Molecular characterization of the type-specific gamma-determinant located on the adenovirus fiber: J.Virol., v. 71, p. 6576-6581.

Fallaux,FJ, A Bout, d V van, I, D J van den Wollenberg, K M Hehir, J Keegan, C Auger, S J Cramer, H van Ormondt, A J van der Eb, D Valerio, R C Hoeben, 1998, New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses: Hum.Gene Ther., v. 9, p. 1909-1917.

Fechner,H, A Haack, H Wang, X Wang, K Eizema, M Pauschinger, R Schoemaker, R Veghel, A Houtsmuller, H P Schultheiss, J Lamers, W Poller, 1999, Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers: Gene Ther., v. 6, p. 1520-1535.

Fechner,H, X Wang, H Wang, A Jansen, M Pauschinger, H Scherubl, J M Bergelson, H P Schultheiss, W Poller, 2000, Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells: Gene Ther., v. 7, p. 1954-1968.

Ferreira,V, N Sidenius, N Tarantino, P Hubert, L Chatenoud, F Blasi, M Korner, 1999, In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis: J.Immunol., v. 162, p. 6442-6450.

Forster,K, V Helbl, T Lederer, S Urlinger, N Wittenburg, W Hillen, 1999, Tetracycline-inducible expression systems with reduced basal activity in mammalian cells: Nucleic Acids Res., v. 27, p. 708-710.

Freundlieb,S, C Schirra-Muller, H Bujard, 1999, A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells: J.Gene Med., v. 1, p. 4-12.

Freytag,SO, K R Rogulski, D L Paielli, J D Gilbert, J H Kim, 1998, A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy [see comments]: Hum.Gene Ther., v. 9, p. 1323-1333.

Fueyo,J, C Gomez-Manzano, R Alemany, P S Lee, T J McDonnell, P Mitlianga, Y X Shi, V A Levin, W K Yung, A P Kyritsis, 2000, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo: Oncogene, v. 19, p. 2-12.

Gambotto,A, T Tuting, D L McVey, I Kovesdi, H Tahara, M T Lotze, P D Robbins, 1999, Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12: Cancer Gene Ther., v. 6, p. 45-53.

Ganly,I, D Kirn, S G Eckhardt, G I Rodriguez, D S Soutar, R Otto, A G Robertson, O Park, M L Gulley, C Heise, D D Von Hoff, S B Kaye, 2000, A phase I study of Onyx-015, an E1B attenuated adenovirus,

administered intratumorally to patients with recurrent head and neck cancer: Clin.Cancer Res., v. 6, p. 798-806.

Gay,E, D Seurin, S Babajko, S Doublier, M Cazillis, M Binoux, 1997, Liver-specific expression of human insulin-like growth factor binding protein-1 in transgenic mice: repercussions on reproduction, ante- and perinatal mortality and postnatal growth: Endocrinology, v. 138, p. 2937-2947.

Geller,AI, X O Breakefield, 1988, A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons: Science, v. 241, p. 1667-1669.

Goldsmith,KT, L D Dion, D T Curiel, R I J Garver, 1998, trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus: Virology, v. 248, p. 406-419.

Goodbourn,S, L Didcock, R E Randall, 2000, Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures: J.Gen.Virol., v. 81 Pt 10, p. 2341-2364.

Goodrum,FD, D A Ornelles, 1998, p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection: J.Virol., v. 72, p. 9479-9490.

Goodrum,FD, D A Ornelles, 1999, Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication: J.Virol., v. 73, p. 7474-7488.

Gossen,M, H Bujard, 1992, Tight control of gene expression in mammalian cells by tetracycline-responsive promoters: Proc.Natl.Acad.Sci.U.S.A., v. 89, p. 5547-5551.

Gossen,M, S Freundlieb, G Bender, G Muller, W Hillen, H Bujard, 1995, Transcriptional activation by tetracyclines in mammalian cells: Science, v. 268, p. 1766-1769.

Gottlieb,TM, M Oren, 1996, p53 in growth control and neoplasia: Biochim.Biophys.Acta, v. 1287, p. 77-102.

Goukassian,D, A Diez-Juan, T Asahara, P Schratzberger, M Silver, T Murayama, J M Isner, V Andres, 2001, Overexpression of p27(Kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis: FASEB J., v. 15, p. 1877-1885.

Graham,FL, J Smiley, W C Russell, R Nairn, 1977, Characteristics of a human cell line transformed by DNA from human adenovirus type 5: J.Gen.Virol., v. 36, p. 59-74.

Greber,UF, P Webster, J Weber, A Helenius, 1996, The role of the adenovirus protease on virus entry into cells: EMBO J., v. 15, p. 1766-1777.

Grim,J, A D'Amico, S Frizelle, J Zhou, R A Kratzke, D T Curiel, 1997, Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel: Clin.Cancer Res., v. 3, p. 2415-2423.

Guo,ZS, L H Wang, R C Eisensmith, S L Woo, 1996, Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer: Gene Ther., v. 3, p. 802-810.

Hafenrichter,DG, K P Ponder, S D Rettinger, S C Kennedy, X Wu, R S Saylors, M W Flye, 1994a, Liver-directed gene therapy: evaluation of liver specific promoter elements: J.Surg.Res., v. 56, p. 510-517.

Hafenrichter,DG, X Wu, S D Rettinger, S C Kennedy, M W Flye, K P Ponder, 1994b, Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes: Blood, v. 84, p. 3394-3404.

Halbert,DN, J R Cutt, T Shenk, 1985, Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff: J.Virol., v. 56, p. 250-257.

Hall,AR, B R Dix, S J O'Carroll, A W Braithwaite, 1998, p53-dependent cell death/apoptosis is required for a productive adenovirus infection [see comments]: Nat.Med., v. 4, p. 1068-1072.

Hallenbeck,PL, Y N Chang, C Hay, D Golightly, D Stewart, J Lin, S Phipps, Y L Chiang, 1999b, A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma: Hum.Gene Ther., v. 10, p. 1721-1733.

Harada,JN, A J Berk, 1999, p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication: J.Virol., v. 73, p. 5333-5344.

Harrod,KS, T W Hermiston, B C Trapnell, W S Wold, J A Whitsett, 1998, Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression: Hum.Gene Ther., v. 9, p. 1885-1898.

Hauck,W, C P Stanners, 1995, Transcriptional regulation of the carcinoembryonic antigen gene. Identification of regulatory elements and multiple nuclear factors: J.Biol.Chem., v. 270, p. 3602-3610.

Hay,JG, N G McElvaney, J Herena, R G Crystal, 1995, Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector: Hum.Gene Ther., v. 6, p. 1487-1496.

Hearing,P, R J Samulski, W L Wishart, T Shenk, 1987, Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome: J.Virol., v. 61, p. 2555-2558.

Hehir,KM, D Armentano, L M Cardoza, T L Choquette, P B Berthelette, G A White, L A Couture, M B Everton, J Keegan, J M Martin, D A Pratt, M P Smith, A E Smith, S C Wadsworth, 1996, Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence: J.Virol., v. 70, p. 8459-8467.

Heideman,DA, P J Snijders, M E Craanen, E Bloemena, C J Meijer, S G Meuwissen, V W van Beusechem, H M Pinedo, D T Curiel, H J Haisma, W R Gerritsen, 2001, Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors: Cancer Gene Ther., v. 8, p. 342-351.

Heise,C, A Sampson-Johannes, A Williams, F McCormick, D D Von Hoff, D H Kirn, 1997, ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]: Nat.Med., v. 3, p. 639-645.

Heise,CC, A Williams, J Olesch, D H Kirn, 1999, Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects: Cancer Gene Ther., v. 6, p. 499-504.

Helbl,V, W Hillen, 1998, Stepwise selection of TetR variants recognizing tet operator 4C with high affinity and specificity: J.Mol.Biol., v. 276, p. 313-318.

Helbl,V, B Tiebel, W Hillen, 1998, Stepwise selection of TetR variants recognizing tet operator 6C with high affinity and specificity: J.Mol.Biol., v. 276, p. 319-324.

Hennighausen,L, R J Wall, U Tillmann, M Li, P A Furth, 1995, Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system: J.Cell Biochem., v. 59, p. 463-472.

Hentges,KE, B Sirry, A C Gingeras, D Sarbassov, N Sonenberg, D Sabatini, A S Peterson, 2001, FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse: Proc.Natl.Acad.Sci.U.S.A, v. 98, p. 13796-13801.

Hermiston,T, 2000, Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer: J.Clin.Invest, v. 105, p. 1169-1172.

Hernandez-Alcoceba,R, M Pihalja, G Nunez, M F Clarke, 2001, Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells: Cancer Gene Ther., v. 8, p. 298-307.

Hernandez-Alcoceba,R, M Pihalja, M S Wicha, M F Clarke, 2000, A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors [In Process Citation]: Hum.Gene Ther., v. 11, p. 2009-2024.

Hidaka,C, E Milano, P L Leopold, J M Bergelson, N R Hackett, R W Finberg, T J Wickham, I Kovesdi, P Roelvink, R G Crystal, 1999, CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts: J.Clin.Invest., v. 103, p. 579-587.

Hierholzer,JC, 1973, Further subgrouping of the human adenoviruses by differential hemagglutination: J.Infect.Dis., v. 128, p. 541-550.

Hirschowitz,EA, R G Crystal, 1999, Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases: Am.J.Respir.Cell Mol.Biol., v. 20, p. 935-941.

Horikoshi,N, A Usheva, J Chen, A J Levine, R Weinmann, T Shenk, 1995, Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression: Mol.Cell Biol., v. 15, p. 227-234.

Horowitz,J, 1999, Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications: Curr.Opin.Mol.Ther., v. 1, p. 500-509.

Horwitz,MS, 1996, in KDHP Fields BN (ed), Fields Virology: Philadelphia, New York, Lippincott-Raven, p. 2149.

Howe,JA, G W Demers, D E Johnson, S E Neugebauer, S T Perry, M T Vaillancourt, B Faha, 2000, Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy: Mol.Ther., v. 2, p. 485-495.

Hu,SX, W Ji, Y Zhou, C Logothetis, H J Xu, 1997, Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression: Cancer Res., v. 57, p. 3339-3343.

Hu,Z, A Garen, 2000, Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy: Proc.Natl.Acad.Sci.U.S.A, v. 97, p. 9221-9225.

Hu,Z, A Garen, 2001, Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer: Proc.Natl.Acad.Sci.U.S.A, v. 98, p. 12180-12185.

Imazu,T, S Shimizu, S Tagami, M Matsushima, Y Nakamura, T Miki, A Okuyama, Y Tsujimoto, 1999, Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability: Oncogene, v. 18, p. 4523-4529.

Imhof,MO, P Chatellard, N Mermod, 2000, A regulatory network for the efficient control of transgene expression: J.Gene Med., v. 2, p. 107-116.

Jackson,RJ, A Kaminski, 1995, Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond: RNA., v. 1, p. 985-1000.

Johnson,DG, J K Schwarz, W D Cress, J R Nevins, 1993, Expression of transcription factor E2F1 induces quiescent cells to enter S phase: Nature, v. 365, p. 349-352.

Kasof,GM, L Goyal, E White, 1999, Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins: Mol.Cell Biol., v. 19, p. 4390-4404.

Kass-Eisler,A, E Falck-Pedersen, D H Elfenbein, M Alvira, P M Buttrick, L A Leinwand, 1994, The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer: Gene Ther., v. 1, p. 395-402.

Kay,MA, P Baley, S Rothenberg, F Leland, L Fleming, K P Ponder, T Liu, M Finegold, G Darlington, W Pokorny, ., 1992, Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes: Proc.Natl.Acad.Sci.U.S.A, v. 89, p. 89-93.

Keblusek,P, J C Dorsman, A F Teunisse, H Teunissen, A J van der Eb, A Zantema, 1999, The adenoviral E1A oncoproteins interfere with the growth-inhibiting effect of the cdk-inhibitor p21(CIP1/WAF1): J.Gen.Virol., v. 80 (Pt 2), p. 381-390.

Khuri,FR, J Nemunaitis, I Ganly, J Arseneau, I F Tannock, L Romel, M Gore, J Ironside, R H MacDougall, C Heise, B Randlev, A M Gillenwater, P Bruso, S B Kaye, W K Hong, D H Kirn, 2000, a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]: Nat.Med., v. 6, p. 879-885.

Kim,IA, Y J Yang, S C Yoon, I B Choi, C S Kay, H C Kwon, C M Kim, Y A Joe, J K Kang, Y K Hong, 2001, Potential of adenoviral p53 gene therapy and irradiation for the treatment of malignant gliomas: Int.J.Oncol., v. 19, p. 1041-1047.

Kistner,A, M Gossen, F Zimmermann, J Jerecic, C Ullmer, H Lubbert, H Bujard, 1996, Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice: Proc.Natl.Acad.Sci.U.S.A., v. 93, p. 10933-10938.

Koch,PE, Z S Guo, S Kagawa, J Gu, J A Roth, B Fang, 2001, Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system: Mol.Ther., v. 3, p. 278-283.

Konig,C, J Roth, M Dobbelstein, 1999, Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein: J.Virol., v. 73, p. 2253-2262.

Koyama,F, H Sawada, H Fujii, H Hamada, T Hirao, M Ueno, H Nakano, 2000, Adenoviral-mediated transfer of escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil [In Process Citation]: Eur.J.Cancer, v. 36, p. 2403-2410.

Kringstein,AM, F M Rossi, A Hofmann, H M Blau, 1998, Graded transcriptional response to different concentrations of a single transactivator: Proc.Natl.Acad.Sci.U.S.A., v. 95, p. 13670-13675.

Kurihara,T, D E Brough, I Kovesdi, D W Kufe, 2000, Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen: J.Clin.Invest, v. 106, p. 763-771.

Ladiwala,U, H Li, J P Antel, J Nalbantoglu, 1999, p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes: J.Neurochem., v. 73, p. 605-611.

Lamartina,S, G Roscilli, C D Rinaudo, E Sporeno, L Silvi, W Hillen, H Bujard, R Cortese, G Ciliberto, C Toniatti, 2002, Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators: Hum.Gene Ther., v. 13, p. 199-210.

Lavia,P, P Jansen-Durr, 1999, E2F target genes and cell-cycle checkpoint control: Bioessays, v. 21, p. 221-230.

Le,M, T Okuyama, S R Cai, S C Kennedy, W M Bowling, M W Flye, K P Ponder, 1997, Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy: Blood, v. 89, p. 1254-1259.

Lee,DK, M Horikoshi, R G Roeder, 1991, Interaction of TFIID in the minor groove of the TATA element: Cell, v. 67, p. 1241-1250.

Lee,SE, R J Jin, S G Lee, S J Yoon, M S Park, D S Heo, H Choi, 2000, Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines: Anticancer Res., v. 20, p. 417-422.

Leong,K, W Lee, A J Berk, 1990, High-level transcription from the adenovirus major late promoter requires downstream binding sites for late-phase-specific factors: J.Virol., v. 64, p. 51-60.

Leuchtenberger,S, A Perz, C Gatz, J W Bartsch, 2001, Conditional cell ablation by stringent tetracycline-dependent regulation of barnase in mammalian cells: Nucleic Acids Res., v. 29, p. E76.

Li,Y, R C Pong, J M Bergelson, M C Hall, A I Sagalowsky, C P Tseng, Z Wang, J T Hsieh, 1999, Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy: Cancer Res., v. 59, p. 325-330.

Li,Y, D C Yu, Y Chen, P Amin, H Zhang, N Nguyen, D R Henderson, 2001, A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin: Cancer Res., v. 61, p. 6428-6436.

Lochmuller,H, A Jani, J Huard, S Prescott, M Simoneau, B Massie, G Karpati, G Acsadi, 1994, Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells: Hum.Gene Ther., v. 5, p. 1485-1491.

Löscher, W.; Ungemach, F. R.; Kroker, R.; Pharmakotherapie bei Haus- und Nutztieren; Parey Buchverlag Berlin 1997, 3. Auflage)

Look,DC, W T Roswit, A G Frick, Y Gris-Alevy, D M Dickhaus, M J Walter, M J Holtzman, 1998, Direct suppression of Stat1 function during adenoviral infection: Immunity., v. 9, p. 871-880.

Loser,P, G S Jennings, M Strauss, V Sandig, 1998, Reactivation of the previously silenced cytomegalovirus major immediate- early promoter in the mouse liver: involvement of NFkappaB: J.Virol., v. 72, p. 180-190.

Lowe,SL, S Rubinchik, T Honda, T J McDonnell, J Y Dong, J S Norris, 2001, Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells: Gene Ther., v. 8, p. 1363-1371.

Lukashok,SA, L Tarassishin, Y Li, M S Horwitz, 2000, An adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis complexes with dynein and a small GTPase: J.Virol., v. 74, p. 4705-4709.

Lusky,M, L Grave, A Dieterle, D Dreyer, M Christ, C Ziller, P Furstenberger, J Kintz, D A Hadji, A Pavirani, M Mehtali, 1999, Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3: J.Virol., v. 73, p. 8308-8319.

Lutz,P, C Kedinger, 1996, Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter: J.Virol., v. 70, p. 1396-1405.

Lutz,P, M Rosa-Calatrava, C Kedinger, 1997, The product of the adenovirus intermediate gene IX is a transcriptional activator: J.Virol., v. 71, p. 5102-5109.

Mannervik,M, S Fan, A C Strom, K Helin, G Akusjarvi, 1999, Adenovirus E4 open reading frame 4-induced dephosphorylation inhibits E1A activation of the E2 promoter and E2F-1-mediated transactivation independently of the retinoblastoma tumor suppressor protein: Virology, v. 256, p. 313-321.

Mano,T, Z Luo, T Suhara, R C Smith, S Esser, K Walsh, 2000, Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions: Hum.Gene Ther., v. 11, p. 1625-1635.

Manome,Y, T Kunieda, P Y Wen, T Koga, D W Kufe, T Ohno, 1998, Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine: Hum.Gene Ther., v. 9, p. 1409-1417.

Mansour,SL, T Grodzicker, R Tjian, 1986, Downstream sequences affect transcription initiation from the adenovirus major late promoter: Mol.Cell Biol., v. 6, p. 2684-2694.

Martin,AB, S Webber, F J Fricker, R Jaffe, G Demmler, D Kearney, Y H Zhang, J Bodurtha, B Gelb, J Ni, 1994, Acute myocarditis. Rapid diagnosis by PCR in children: Circulation, v. 90, p. 330-339.

Maruyama,K, Y Akiyama, N Nara-Ashizawa, T Hojo, J Y Cheng, H Mizuguchi, T Hayakawa, K Yamaguchi, 2001, Adenovirus-Mediated MUC1 gene transduction into human blood-derived dendritic cells: J.Immunother., v. 24, p. 345-353.

Massie,B, F Couture, L Lamoureux, D D Mosser, C Guilbault, P Jolicoeur, F Belanger, Y Langelier, 1998, Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette: J.Virol., v. 72, p. 2289-2296.

Mathias,P, T Wickham, M Moore, G Nemerow, 1994, Multiple adenovirus serotypes use alpha v integrins for infection: J.Virol., v. 68, p. 6811-6814.

Matsubara,S, Y Wada, T A Gardner, M Egawa, M S Park, C L Hsieh, H E Zhau, C Kao, S Kamidono, J Y Gillenwater, L W Chung, 2001, A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis: Cancer Res., v. 61, p. 6012-6019.

Matthews,DA, D Cummings, C Evelegh, F L Graham, L Prevec, 1999, Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein: J.Gen.Virol., v. 80 (Pt 2), p. 345-353.

Mazzolini,G, C Qian, I Narvaiza, M Barajas, F Borras-Cuesta, X Xie, M Duarte, I Melero, J Prieto, 2000, Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level: Hum.Gene Ther., v. 11, p. 113-125.

McDonald,C, N C Reich, 1999, Cooperation of the transcriptional coactivators CBP and p300 with Stat6: J.Interferon Cytokine Res., v. 19, p. 711-722.

Mei,YF, G Wadell, 1996, Epitopes and hemagglutination binding domain on subgenus B:2 adenovirus fibers: J.Virol., v. 70, p. 3688-3697.

Miller,CR, D J Buchsbaum, P N Reynolds, J T Douglas, G Y Gillespie, M S Mayo, D Raben, D T Curiel, 1998, Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer: Cancer Res., v. 58, p. 5738-5748.

Minaguchi,T, T Mori, Y Kanamori, M Matsushima, H Yoshikawa, Y Taketani, Y Nakamura, 1999, Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene: Cancer Res., v. 59, p. 6063-6067.

Mizuguchi,H, T Hayakawa, 2001, Characteristics of adenovirus-mediated tetracycline-controllable expression system: Biochim.Biophys.Acta, v. 1568, p. 21-29.

Molin,M, M C Shoshan, K Ohman-Forslund, S Linder, G Akusjarvi, 1998, Two novel adenovirus vector systems permitting regulated protein expression in gene transfer experiments: J.Virol., v. 72, p. 8358-8361.

Moorhead,JW, G H Clayton, R L Smith, J Schaack, 1999, A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears: J.Virol., v. 73, p. 1046-1053.

Morgan,DO, 1995, Principles of CDK regulation: Nature, v. 374, p. 131-134.

Morral,N, W O'Neal, K Rice, M Leland, J Kaplan, P A Piedra, H Zhou, R J Parks, R Velji, E Aguilar-Cordova, S Wadsworth, F L Graham, S Kochanek, K D Carey, A L Beaudet, 1999, Administration of

helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons: Proc.Natl.Acad.Sci.U.S.A., v. 96, p. 12816-12821.

Morral,N, R J Parks, H Zhou, C Langston, G Schiedner, J Quinones, F L Graham, S Kochanek, A L Beaudet, 1998, High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity: Hum.Gene Ther., v. 9, p. 2709-2716.

Morsy,MA, M Gu, S Motzel, J Zhao, J Lin, Q Su, H Allen, L Franlin, R J Parks, F L Graham, S Kochanek, A J Bett, C T Caskey, 1998, An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene: Proc.Natl.Acad.Sci.U.S.A., v. 95, p. 7866-7871.

Motoi,F, M Sunamura, L Ding, D G Duda, Y Yoshida, W Zhang, S Matsuno, H Hamada, 2000, Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus: Hum.Gene Ther., v. 11, p. 223-235.

Muzyczka,N, 1992, Use of adeno-associated virus as a general transduction vector for mammalian cells: Curr.Top.Microbiol.Immunol., v. 158:97-129., p. 97-129.

Nagata,S, P Golstein, 1995, The Fas death factor: Science, v. 267, p. 1449-1456.

Narvaiza,I, G Mazzolini, M Barajas, M Duarte, M Zaratiegui, C Qian, I Melero, J Prieto, 2000, Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy: J.Immunol., v. 164, p. 3112-3122.

Nemerow,GR, P L Stewart, 1999, Role of alpha(v) integrins in adenovirus cell entry and gene delivery: Microbiol.Mol.Biol.Rev., v. 63, p. 725-734.

Nemunaitis,J, C Cunningham, A Buchanan, A Blackburn, G Edelman, P Maples, G Netto, A Tong, B Randlev, S Olson, D Kirn, 2001, Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity: Gene Ther., v. 8, p. 746-759.

Nicklin,SA, P N Reynolds, M J Brosnan, S J White, D T Curiel, A F Dominiczak, A H Baker, 2001, Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium: Hypertension, v. 38, p. 65-70.

No,D, T P Yao, R M Evans, 1996, Ecdysone-inducible gene expression in mammalian cells and transgenic mice: Proc.Natl.Acad.Sci.U.S.A, v. 93, p. 3346-3351.

Norrby,E, 1969, The structural and functional diversity of Adenovirus capsid components: J.Gen.Virol., v. 5, p. 221-236.

Ohwada,A, E A Hirschowitz, R G Crystal, 1996, Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5- fluorocytosine to suppress the growth of colon carcinoma metastatic to liver: Hum.Gene Ther., v. 7, p. 1567-1576.

Okuyama,T, R M Huber, W Bowling, R Pearline, S C Kennedy, M W Flye, K P Ponder, 1996, Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo: Hum.Gene Ther., v. 7, p. 637-645.

Ornelles,DA, T Shenk, 1991, Localization of the adenovirus early region 1B 55-kilodalton protein during lytic infection: association with nuclear viral inclusions requires the early region 4 34-kilodalton protein: J.Virol., v. 65, p. 424-429.

Paielli,DL, M S Wing, K R Rogulski, J D Gilbert, A Kolozsvary, J H Kim, J Hughes, M Schnell, T Thompson, S O Freytag, 2000, Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse: Mol.Ther., v. 1, p. 263-274.

Pastore,L, N Morral, H Zhou, R Garcia, R J Parks, S Kochanek, F L Graham, B Lee, A L Beaudet, 1999, Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors: Hum.Gene Ther., v. 10, p. 1773-1781.

Pastoret,PP, B Brochier, 1992, Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies: Dev.Biol.Stand., v. 79:105-11., p. 105-111.

Paulson,M, S Pisharody, L Pan, S Guadagno, A L Mui, D E Levy, 1999, Stat protein transactivation domains recruit p300/CBP through widely divergent sequences: J.Biol.Chem., v. 274, p. 25343-25349.

Pauschinger,M, A Doerner, U Kuehl, P L Schwimmbeck, W Poller, R Kandolf, H P Schultheiss, 1999, Enteroviral RNA Replication in the Myocardium of Patients With Left Ventricular Dysfunction and Clinically Suspected Myocarditis: Circulation, v. 99, p. 889-895.

Pearson,AS, F R Spitz, S G Swisher, M Kataoka, M G Sarkiss, R E Meyn, T J McDonnell, R J Cristiano, J A Roth, 2000, Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells: Clin.Cancer Res., v. 6, p. 887-890.

Peng,XY, J H Won, T Rutherford, T Fujii, D Zelterman, G Pizzorno, E Sapi, J Leavitt, B Kacinski, R Crystal, P Schwartz, A Deisseroth, 2001, The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines: Cancer Res., v. 61, p. 4405-4413.

Pengue,G, L Lania, 1996, Kruppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements: Proc.Natl.Acad.Sci.U.S.A, v. 93, p. 1015-1020.

Perlmutter,DH, 1995, Clinical manifestations of alpha 1-antitrypsin deficiency: Gastroenterol.Clin.North Am., v. 24, p. 27-43.

Perrotte,P, M Wood, J W Slaton, D R Wilson, L Pagliaro, R E Price, C P Dinney, 2000, Biosafety of in vivo adenovirus-p53 intravesical administration in mice: Urology, v. 56, p. 155-159.

Philipson,L, 1984, Structure and assembly of adenoviruses: Curr.Top.Microbiol.Immunol., v. 109, p. 1-52.

Ponder,KP, S Gupta, F Leland, G Darlington, M Finegold, J DeMayo, F D Ledley, J R Chowdhury, S L Woo, 1991, Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation: Proc.Natl.Acad.Sci.U.S.A, v. 88, p. 1217-1221.

Printz,MA, A M Gonzalez, M Cunningham, D L Gu, M Ong, G F Pierce, S L Aukerman, 2000, Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors: Hum.Gene Ther., v. 11, p. 191-204.

Pugh,BF, R Tjian, 1992, Diverse transcriptional functions of the multisubunit eukaryotic TFIID complex: J.Biol.Chem., v. 267, p. 679-682.

Putzer,BM, J L Bramson, C L Addison, M Hitt, P M Siegel, W J Muller, F L Graham, 1998, Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer: Hum.Gene Ther., v. 9, p. 707-718.

Ralph,GS, A Bienemann, T C Harding, M Hopton, J Henley, J B Uney, 2000, Targeting of tetracycline-regulatable transgene expression specifically to neuronal and glial cell populations using adenoviral vectors: Neuroreport, v. 11, p. 2051-2055.

Rancourt,C, A Piche, J Gomez-Navarro, M Wang, R D Alvarez, G P Siegal, G M Fuller, S A Jones, D T Curiel, 1999, Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy: Clin.Cancer Res., v. 5, p. 43-50.

Rao,L, D Perez, E White, 1996, Lamin proteolysis facilitates nuclear events during apoptosis: J.Cell Biol., v. 135, p. 1441-1455.

Ray,P, W Tang, P Wang, R Homer, C Kuhn, R A Flavell, J A Elias, 1997, Regulated overexpression of interleukin 11 in the lung. Use to dissociate development-dependent and -independent phenotypes: J.Clin.Invest., v. 100, p. 2501-2511.

Rekosh,DM, W C Russell, A J Bellet, A J Robinson, 1977, Identification of a protein linked to the ends of adenovirus DNA: Cell, v. 11, p. 283-295.

Rendahl,KG, D Quiroz, M Ladner, M Coyne, J Seltzer, W C Manning, J A Escobedo, 2002, Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors: Hum.Gene Ther., v. 13, p. 335-342.

Rettinger,SD, S C Kennedy, X Wu, R L Saylors, D G Hafenrichter, M W Flye, K P Ponder, 1994, Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction: Proc.Natl.Acad.Sci.U.S.A, v. 91, p. 1460-1464.

Ribieras,S, C Tomasetto, M C Rio, 1998, The pS2/TFF1 trefoil factor, from basic research to clinical applications: Biochim.Biophys.Acta, v. 1378, p. F61-F77.

Rio,MC, P Chambon, 1990, The pS2 gene, mRNA, and protein: a potential marker for human breast cancer: Cancer Cells, v. 2, p. 269-274.

Rivera,VM, T Clackson, S Natesan, R Pollock, J F Amara, T Keenan, S R Magari, T Phillips, N L Courage, F Cerasoli, Jr., D A Holt, M Gilman, 1996, A humanized system for pharmacologic control of gene expression: Nat.Med., v. 2, p. 1028-1032.

Rizzuto,G, M Cappelletti, D Maione, R Savino, D Lazzaro, P Costa, I Mathiesen, R Cortese, G Ciliberto, R Laufer, N La Monica, E Fattori, 1999, Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation: Proc.Natl.Acad.Sci.U.S.A, v. 96, p. 6417-6422.

Robinson,BW, S A Mukherjee, A Davidson, S Morey, A W Musk, I Ramshaw, D Smith, R Lake, T Haenel, M Garlepp, J Marley, C Leong, I Caminschi, B Scott, 1998, Cytokine gene therapy or infusion as treatment for solid human cancer: J.Immunother., v. 21, p. 211-217.

Rodriguez,I, K Matsuura, K Khatib, J C Reed, S Nagata, P Vassalli, 1996, A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection: J.Exp.Med., v. 183, p. 1031-1036.

Rodriguez,R, E R Schuur, H Y Lim, G A Henderson, J W Simons, D R Henderson, 1997, Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells: Cancer Res., v. 57, p. 2559-2563.

Rogulski,KR, S O Freytag, K Zhang, J D Gilbert, D L Paielli, J H Kim, C C Heise, D H Kirn, 2000, In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy: Cancer Res., v. 60, p. 1193-1196.

Rogulski,KR, K Zhang, A Kolozsvary, J H Kim, S O Freytag, 1997, Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy: Clin.Cancer Res., v. 3, p. 2081-2088.

Rossi,FM, O M Guicherit, A Spicher, A M Kringstein, K Fatyol, B T Blakely, H M Blau, 1998, Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16: Nat.Genet., v. 20, p. 389-393.

Rothmann,T, A Hengstermann, N J Whitaker, M Scheffner, H H zur, 1998, Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells: J.Virol., v. 72, p. 9470-9478.

Ruan,H, J Wang, L Hu, C S Lin, K R Lamborn, D F Deen, 1999, Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX: Neoplasia., v. 1, p. 431-437.

Rubinchik,S, R Ding, A J Qiu, F Zhang, J Dong, 2000, Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system: Gene Ther., v. 7, p. 875-885.

Rubinchik,S, D Wang, H Yu, F Fan, M Luo, J S Norris, J Y Dong, 2001, A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression: Mol.Ther., v. 4, p. 416-426.

Russell,WC, 2000, Update on adenovirus and its vectors: J.Gen.Virol., v. 81 Pt 11:2573-604, p. 2573-2604.

Sander,A, A Guth, H R Brenner, V Witzemann, 2000, Gene transfer into individual muscle fibers and conditional gene expression in living animals: Cell Tissue Res., v. 301, p. 397-403.

Sandig,V, R Youil, A J Bett, L L Franlin, M Oshima, D Maione, F Wang, M L Metzker, R Savino, C T Caskey, 2000, Optimization of the helper-dependent adenovirus system for production and potency in vivo: Proc.Natl.Acad.Sci.U.S.A., v. 97, p. 1002-1007.

Sandy,P, M Gostissa, V Fogal, L D Cecco, K Szalay, R J Rooney, C Schneider, G Del Sal, 2000, p53 is involved in the p120E4F-mediated growth arrest: Oncogene, v. 19, p. 188-199.

Saphire,AC, T Guan, E C Schirmer, G R Nemerow, L Gerace, 2000, Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70: J.Biol.Chem., v. 275, p. 4298-4304.

Sasaki,R, T Shirakawa, Z J Zhang, A Tamekane, A Matsumoto, K Sugimura, M Matsuo, S Kamidono, A Gotoh, 2001, Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells: Int.J.Radiat.Oncol.Biol.Phys., v. 51, p. 1336-1345.

Sauthoff,H, S Heitner, W N Rom, J G Hay, 2000, Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector: Hum.Gene Ther., v. 11, p. 379-388.

Serguera,C, D Bohl, E Rolland, P Prevost, J M Heard, 1999, Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells: Hum.Gene Ther., v. 10, p. 375-383.

Shao,R, M C Hu, B P Zhou, S Y Lin, P J Chiao, R H von Lindern, B Spohn, M C Hung, 1999, E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities: J.Biol.Chem., v. 274, p. 21495-21498.

Shenk T., 1996, Adenoviridae: The viruses and their replication, in Fields BN, Knipe DM, and Howley PM (eds), Fields Virology: Philadelphia, New York, Lippincott-Raven, p. 2111-2148.

Shi,Y, E Seto, L S Chang, T Shenk, 1991, Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein: Cell, v. 67, p. 377-388.

Shimada,H, T Shimizu, T Ochiai, T L Liu, H Sashiyama, A Nakamura, H Matsubara, Y Gunji, S Kobayashi, M Tagawa, S Sakiyama, T Hiwasa, 2001, Preclinical study of adenoviral p53 gene therapy for esophageal cancer: Surg.Today, v. 31, p. 597-604.

Shinoura,N, Y Yoshida, R Tsunoda, M Ohashi, W Zhang, A Asai, T Kirino, H Hamada, 1999, Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas: Cancer Res., v. 59, p. 3411-3416.

Shirakawa,T, A Gotoh, T A Gardner, C Kao, Z J Zhang, S Matsubara, Y Wada, N Hinata, M Fujisawa, K Hanioka, M Matsuo, S Kamidono, 2000, p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model: J.Gene Med., v. 2, p. 426-432.

Staba,MJ, T J Wickham, I Kovesdi, D E Hallahan, 2000, Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models: Cancer Gene Ther., v. 7, p. 13-19.

Stebbins,MJ, S Urlinger, G Byrne, B Bello, W Hillen, J C Yin, 2001, Tetracycline-inducible systems for Drosophila: Proc.Natl.Acad.Sci.U.S.A, v. 98, p. 10775-10780.

Steinwaerder,DS, C A Carlson, A Lieber, 1999, Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats: J.Virol., v. 73, p. 9303-9313.

Steinwaerder,DS, C A Carlson, D L Otto, Z Y Li, S Ni, A Lieber, 2001, Tumor-specific gene expression in hepatic metastases by a replication- activated adenovirus vector: Nat.Med., v. 7, p. 240-243.

Sterman,DH, J Treat, L A Litzky, K M Amin, L Coonrod, K Molnar-Kimber, A Recio, L Knox, J M Wilson, S M Albelda, L R Kaiser, 1998, Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma: Hum.Gene Ther., v. 9, p. 1083-1092.

Stewart,PL, R M Burnett, M Cyrklaff, S D Fuller, 1991, Image reconstruction reveals the complex molecular organization of adenovirus: Cell, v. 67, p. 145-154.

Stryer L., Biochemie, 2. korr. Nachdruck der neubearb. Aufl. 1990, Spektrum Akad. Verlag 1994

Subramanian,T, J M Boyd, G Chinnadurai, 1995, Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins: Oncogene, v. 11, p. 2403-2409.

Suzuki,K, J Fueyo, V Krasnykh, P N Reynolds, D T Curiel, R Alemany, 2001, A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency: Clin.Cancer Res., v. 7, p. 120-126.

Tai,YT, T Strobel, D Kufe, S A Cannistra, 1999, In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene: Cancer Res., v. 59, p. 2121-2126.

Tollefson,AE, T W Hermiston, D L Lichtenstein, C F Colle, R A Tripp, T Dimitrov, K Toth, C E Wells, P C Doherty, W S Wold, 1998, Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells: Nature, v. 392, p. 726-730.

Tollefson,AE, J S Ryerse, A Scaria, T W Hermiston, W S Wold, 1996a, The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants: Virology, v. 220, p. 152-162.

Tollefson,AE, A Scaria, T W Hermiston, J S Ryerse, L J Wold, W S Wold, 1996b, The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells: J.Virol., v. 70, p. 2296-2306.

Toloza,EM, K Hunt, S Swisher, W McBride, R Lau, S Pang, K Rhoades, T Drake, A Belldegrun, J Glaspy, J S Economou, 1996, In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector: Cancer Gene Ther., v. 3, p. 11-17.

Toth,M, W Doerfler, T Shenk, 1992, Adenovirus DNA replication facilitates binding of the MLTF/USF transcription factor to the viral major late promoter within infected cells: Nucleic Acids Res., v. 20, p. 5143-5148.

Turnell,AS, R J Grand, P H Gallimore, 1999, The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status: J.Virol., v. 73, p. 2074-2083.

Tuting,T, J Steitz, J Bruck, A Gambotto, K Steinbrink, A B DeLeo, P Robbins, J Knop, A H Enk, 1999, Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity: J.Gene Med., v. 1, p. 400-406.

Urlinger,S, U Baron, M Thellmann, M T Hasan, H Bujard, W Hillen, 2000, Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity: Proc.Natl.Acad.Sci.U.S.A., v. 97, p. 7963-7968.

van der Eb,MM, S J Cramer, Y Vergouwe, F H Schagen, J H van Krieken, A J van der Eb, I H Rinkes, d van, V, R C Hoeben, 1998, Severe hepatic dysfunction after adenovirus-mediated transfer of the

herpes simplex virus thymidine kinase gene and ganciclovir administration: Gene Ther., v. 5, p. 451-458.

Varda-Bloom,N, A Shaish, A Gonen, K Levanon, S Greenbereger, S Ferber, H Levkovitz, D Castel, I Goldberg, A Afek, Y Kopolovitc, D Harats, 2001, Tissue-specific gene therapy directed to tumor angiogenesis: Gene Ther., v. 8, p. 819-827.

Viswalingam,ND, 1993, Adenovirus keratoconjunctivitis: an enigma: Eye, v. 7, p. 5-7.

Wadell,G, A Allard, M Johansson, L Svensson, I Uhnoo, 1987, Enteric adenoviruses: Ciba.Found.Symp., v. 128:63-91., p. 63-91.

Wan,Y, P Emtage, R Foley, R Carter, J Gauldie, 1999, Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression: Int.J.Oncol., v. 14, p. 771-776.

Wang,HG, Y Rikitake, M C Carter, P Yaciuk, S E Abraham, B Zerler, E Moran, 1993, Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth: J.Virol., v. 67, p. 476-488.

White,E, R Cipriani, 1990, Role of adenovirus E1B proteins in transformation: altered organization of intermediate filaments in transformed cells that express the 19-kilodalton protein: Mol.Cell Biol., v. 10, p. 120-130.

Wickham,TJ, 2000, Targeting adenovirus: Gene Ther., v. 7, p. 110-114.

Wickham,TJ, P W Roelvink, D E Brough, I Kovesdi, 1996, Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types: Nat.Biotechnol., v. 14, p. 1570-1573.

Wickham,TJ, E Tzeng, L L Shears, P W Roelvink, Y Li, G M Lee, D E Brough, A Lizonova, I Kovesdi, 1997, Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins: J.Virol., v. 71, p. 8221-8229.

Wildner,O, R M Blaese, J C Morris, 1999, Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase: Cancer Res., v. 59, p. 410-413.

Wold,WS, A E Tollefson, T W Hermiston, 1995, E3 transcription unit of adenovirus: Curr.Top.Microbiol.Immunol., v. 199 (Pt 1), p. 237-274.

Wolf,JK, T E Kim, D Fightmaster, D Bodurka, D M Gershenson, G Mills, J T Wharton, 1999, Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus: Gynecol.Oncol., v. 73, p. 27-34.

Wolf,LA, S M Laster, 1999, Characterization of arachidonic acid-induced apoptosis: Cell Biochem.Biophys., v. 30, p. 353-368.

Xie,W, L T Chow, A J Paterson, E Chin, J E Kudlow, 1999, Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice: Oncogene, v. 18, p. 3593-3607.

Ye,X, V M Rivera, P Zoltick, F Cerasoli, Jr., M A Schnell, G Gao, J V Hughes, M Gilman, J M Wilson, 1999, Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer: Science, v. 283, p. 88-91.

Yoshimura,I, S Suzuki, T Tadakuma, M Hayakawa, 2001, Suicide gene therapy on LNCaP human prostate cancer cells: Int.J.Urol., v. 8, p. S5-S8.

Yu,DC, Y Chen, M Seng, J Dilley, D R Henderson, 1999a, The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts: Cancer Res., v. 59, p. 4200-4203.

Yu,DC, G T Sakamoto, D R Henderson, 1999b, Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy: Cancer Res., v. 59, p. 1498-1504.

Yull,FE, R M Wallace, A J Clark, 1995, Restricted tissue-specific but correct developmental expression mediated by a short human alpha 1AT promoter fragment in transgenic mice: Transgenic Res., v. 4, p. 70-74.

Zabner,J, M Chillon, T Grunst, T O Moninger, B L Davidson, R Gregory, D Armentano, 1999, A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia: J.Virol., v. 73, p. 8689-8695.

Zheng,C, A T Hoque, V R Braddon, B J Baum, B C O'Connell, 2001, Evaluation of salivary gland acinar and ductal cell-specific promoters in vivo with recombinant adenoviral vectors: Hum.Gene Ther., v. 12, p. 2215-2223.

Zhu,Z, B Ma, R J Homer, T Zheng, J A Elias, 2001, Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice: J.Biol.Chem., v. 276, p. 25222-25229.